RayKnowChina Research Map
Shortlist

RecruitingLung cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation

An open trial on lung cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page
  2. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06956001, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 9

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (9 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Not used for biopsy during screening

    Inclusion criterion 5

    Histologically/cytologically confirmed non-squamous NSCLC, classified as:

    Inclusion criterion 6

  3. Metastatic (Stage IV) (Based on UICC/AJCC 8th edition TNM staging)

    Inclusion criterion 8

  4. Allowed if: Prior (neo)adjuvant/definitive chemoradiotherapy completed ≥12 months before recurrence/progression

    Inclusion criterion 14

    >30 Gy thoracic radiotherapy within 6 months or non-thoracic radiotherapy within 4 weeks prior to first dose (brain radiotherapy exceptions per Inclusion Criterion #12).

    Exclusion criterion 5

    Major trauma/surgery within 4 weeks prior to treatment initiation.

    Exclusion criterion 10

    Residual toxicity >Grade 1 (per NCI CTCAE v5.0) from prior anticancer therapy (except alopecia/neuropathy).

    Exclusion criterion 29

  5. ECOG performance status 0-1.

    Inclusion criterion 15

  6. Central lab-confirmed EGFR PACC or L861Q mutation (If tumor tissue is unavailable due to inaccessible lesions, sponsor consultation is required.)

    Inclusion criterion 12

  7. At least one measurable lesion per RECIST v1.1, meeting the following:

    Inclusion criterion 3

  8. Other malignancies cured by radical therapy ≥3 years prior

    Exclusion criterion 32

  9. Pregnancy/lactation or planned pregnancy within 6 months post-treatment.

    Exclusion criterion 33

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06956001, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntarily sign the informed consent form (ICF).
  • Age ≥18 years at the time of ICF signing.
  • At least one measurable lesion per RECIST v1.1, meeting the following:
  • No prior local therapy (e.g., radiotherapy)
  • Not used for biopsy during screening
  • Histologically/cytologically confirmed non-squamous NSCLC, classified as:
  • Locally advanced (Stage IIIB/IIIC, unsuitable for curative surgery and/or definitive chemoradiotherapy)
  • Metastatic (Stage IV) (Based on UICC/AJCC 8th edition TNM staging)
  • Agreement to provide:
  • Recent tumor tissue (from untreated lesions)
  • Blood samples
  • Central lab-confirmed EGFR PACC or L861Q mutation (If tumor tissue is unavailable due to inaccessible lesions, sponsor consultation is required.)
  • No prior systemic therapy for advanced/metastatic NSCLC.
  • Allowed if: Prior (neo)adjuvant/definitive chemoradiotherapy completed ≥12 months before recurrence/progression
  • ECOG performance status 0-1.
  • Life expectancy ≥12 weeks.
  • Adequate bone marrow/organ function within 14 days before treatment (no transfusion/G-CSF within 2 weeks prior).
  • Women of childbearing potential (WOCBP):
  • Abstinence or contraception use
  • No egg donation
  • Non-sterilized males:
  • Abstinence or contraception use
  • No sperm donation
  • CNS metastases allowed if protocol-specified criteria are met.

Exclusion Criteria:

  • Histologically/cytologically confirmed tumor with >10% neuroendocrine carcinoma, sarcomatoid carcinoma, or squamous cell components.
  • Known ALK-positive, ROS1-positive, RET fusion-positive, NTRK fusion-positive, BRAF V600E mutation, MET exon 14 skipping mutation, or other targetable alterations with approved therapies.
  • Prior treatments including:
  • Systemic anti-tumor therapy for advanced/metastatic NSCLC (e.g., chemotherapy/targeted/immunotherapy). Neoadjuvant/adjuvant therapy exceptions per Inclusion Criterion #6.
  • >30 Gy thoracic radiotherapy within 6 months or non-thoracic radiotherapy within 4 weeks prior to first dose (brain radiotherapy exceptions per Inclusion Criterion #12).
  • Any prior EGFR-targeted therapy (including investigational EGFR-TKIs, mAbs, bispecific antibodies, etc.).
  • Strong CYP3A4 inhibitors within 7 days or inducers within 21 days prior to first dose.
  • Anticancer traditional Chinese medicines within 2 weeks prior to first dose.
  • Non-specific immunomodulators (e.g., interferon, IL-2, thymosin) within 2 weeks prior to first dose.
  • Major trauma/surgery within 4 weeks prior to treatment initiation.
  • Clinically significant gastrointestinal abnormalities, including:
  • Moderate/severe atrophic gastritis
  • GI obstruction/perforation
  • Chronic diarrhea/short bowel syndrome
  • Major upper GI surgery (e.g., gastrectomy)
  • Inflammatory bowel disease (Crohn's/ulcerative colitis) or active intestinal inflammation
  • Inability to swallow tablets
  • Uncontrolled systemic diseases.
  • Severe acute/chronic infections.
  • Interstitial lung disease (ILD)/non-infectious pneumonia:
  • History requiring clinical intervention
  • Current presence
  • Suspicious imaging findings unresolved at screening
  • Clinically significant cardiovascular dysfunction (active or history).
  • Tumor invasion of critical adjacent structures (heart/esophagus/SVC etc.) with high bleeding/fistula risk. Exceptions may be considered if investigator assesses minimal risk.
  • Pulmonary comorbidities causing severe impairment, including:
  • Baseline lung diseases (e.g., pulmonary embolism [≤3 months], severe asthma/COPD/restrictive disease)
  • Autoimmune/connective tissue disorders with pulmonary involvement (e.g., rheumatoid arthritis, sarcoidosis)
  • Residual toxicity >Grade 1 (per NCI CTCAE v5.0) from prior anticancer therapy (except alopecia/neuropathy).
  • Concurrent malignancies except:
  • Cured localized skin cancers (BCC/SCC), superficial bladder cancer, cervical/breast DCIS, or papillary thyroid cancer
  • Other malignancies cured by radical therapy ≥3 years prior
  • Pregnancy/lactation or planned pregnancy within 6 months post-treatment.
  • Inability to comply with study procedures/follow-up.
  • Known hypersensitivity to furmonertinib or excipients.
  • History of allergic reactions to pemetrexed/cisplatin/carboplatin.
  • Other exclusionary per investigator judgment, including:
  • Alcohol/drug abuse
  • Severe comorbidities (including psychiatric) requiring treatment
  • Critical laboratory abnormalities
  • Social/familial factors compromising safety/data collection

Quoted from ClinicalTrials.gov, NCT06956001, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06956001, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06956001